ストックスクリーナーアプリを入手
2.72
1.09%
-0.03
アフターアワーズ：
2.72
Protalix BioTherapeutics Inc. (PLX) 最新ニュース
Protalix at Morgan Stanley conference: rare-disease growth in focus By Investing.com - Investing.com Canada
Director at Protalix (NYSE: PLX) gets options expiring 2036 plus 8,500 RSUs - Stock Titan
PLX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
Protalix BioTherapeutics Grants 168,000 Derivative Securities to Executive Naos Yaron (AMEX: PLX) - Kalkine Media
Protalix BioTherapeutics (AMEX: PLX) Grants 25,500 Derivative Securities to Insider Forster Eliot - Kalkine Media
Protalix CFO is scheduled for two New York appearances this month - Stock Titan
Stock awards for Protalix (PLX) director vest quarterly to 2036 - Stock Titan
Protalix (NYSE: PLX) director receives new options and RSUs - Stock Titan
Protalix (NYSE: PLX) sets CEO equity to 3-year vesting, change-in-control terms - stocktitan.net
Yaron Naos awarded new equity at Protalix BioTherapeutics (PLX) - Stock Titan
Director at Protalix BioTherapeutics (PLX) gets new options and stock units - Stock Titan
Protalix (PLX) awards Amos Bar‑Shalev new 3‑year equity grant - Stock Titan
Board member at Protalix (PLX) gets new stock and option grant - Stock Titan
Zacks Research Issues Pessimistic Outlook for PLX Earnings - MarketBeat
Protalix (PLX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Protalix (PLX) Q2 2026 Earnings Call Transcript - The Motley Fool
Protalix (PLX) Q2 2026 Filing Snapshot: EPS Clears the Reported Estimate in the Current Update; Share-Price Check - dars.gov.et
Protalix BioTherapeutics (NYSEAMERICAN:PLX) Advances Plant-Cell Protein Programs - Kalkine Media
Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PLX: Elfabrio Estimates Up - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ... - Yahoo! Finance Canada
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highl - GuruFocus
Earnings call transcript: Protalix posts stronger Q2 2026 revenue, shares slip premarket - Investing.com
Protalix BioTherapeutics Inc (PLX) Reports Q2 Earnings: $19.8M R - GuruFocus
Protalix BioTherapeutics, Inc. (PLX) Q2 FY2026 earnings call transcript - Yahoo Finance
Form 8K Protalix Biotherapeutics Inc For: 12 August By Investing.com - Investing.com South Africa
Protalix BioTherapeutics reports Q2 revenue gro... - Pluang
Protalix BioTherapeutics, Inc. 2026: Revenue $19.9M, EPS $0.05— 10-Q Summary - TradingView
Protalix BioTherapeutics (PLX) swings to $22.1M H1 profit on Elfabrio milestone - Stock Titan
Protalix Posts $19.9 Million Q2 Revenue and $3.8 Million Net Income - Quiver Quantitative
Protalix BioTherapeutics reports $53.6M YTD revenue, $22.1M net income in H1 2026 - TradingView
Protalix: Q2 Earnings Snapshot - 10TV
Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Year 2026 - marketscreener.com
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 - PR Newswire
Protalix BioTherapeutics (PLX) Slips 1% as Shares Hover Between Support and ResistanceFloat Adjusted Cap - dars.gov.et
Protalix BioTherapeutics, Inc. Share Price Live Today – AMEX:PLX Stock Price, Chart, News, History - Upstox
Earnings Preview: PLX to Report Financial Results Pre-market on August 12 - Moomoo
Protalix BioTherapeutics (PLX) Edges Higher Amid Consolidation Near SupportRetail Driven Moves - vinanet.vn
BlackRock (NYSE: BLK) discloses 5.02% ownership in Protalix BioTherapeutics (PLX) - Stock Titan
Protalix Biotherapeutics Inc (PLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Price to earnings forward of Protalix Biotherapeutics, Inc. – MUN:PBDA - TradingView
Protalix Biotherapeutics Inc (PLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Protalix Biotherapeutics Inc (PLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PLX|Protalix Biotherapeutics Inc|Price:2.640|Chg%:-0.090 - TradingKey
PLX|Protalix Biotherapeutics Inc|Price:2.440|Chg%:+0.070 - TradingKey
Protalix Biotherapeutics Inc (PLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Protalix Biotherapeutics Inc (PLX) Institutional Confidence - TradingKey
Protalix Biotherapeutics Inc (PLX) Cash Flow - TradingKey
Protalix Biotherapeutics Inc (PLX) Earnings Date & Reports & Earnings News - TradingKey
Protalix BioTherapeutics Market Sentiment - Benzinga España
PLX|Protalix Biotherapeutics Inc|Price:2.220|Chg%:-0.145 - TradingKey
Protalix Biotherapeutics Inc (PLX) Balance Sheet - TradingKey
Protalix Biotherapeutics Inc (PLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Protalix Biotherapeutics Inc (PLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Protalix Biotherapeutics, Inc. Revenue Breakdown – FWB:PBDA - TradingView
Protalix BioTherapeutics (PLX) Holds Steady at $2.37 — Key Levels to WatchHedge Fund Exposure - dars.gov.et
Protalix BioTherapeutics Holds Steady at $2.37 Amid Trading LullContinuation Pattern Picks - dars.gov.et
ETFs Investing in Protalix Biotherapeutics, Inc. Stocks - TradingView
PLXProtalix BioTherapeutics Inc Volatility & Greeks - Finviz
Protalix BioTherapeutics (PLX) Holds Steady Near Support Amid Low VolatilityMoney Flow Index - dars.gov.et
Price to book forward of Protalix Biotherapeutics, Inc. – SWB:PBDA - TradingView
PLX Q1 2026 Earnings: Stunning EPS Surprise Driven by Operational StrengthsCEO Earnings Statement - dars.gov.et
Price to sales forward of Protalix BioTherapeutics, Inc. (DE) – AMEX:PLX - TradingView
Price to sales forward of Protalix Biotherapeutics, Inc. – SWB:PBDA - TradingView
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):